RESUMO
Herein, binary heteronanosheets made of ultrathin ReS2 nanosheets and reduced graphene oxide (RGO) with either a two-dimensional (2D) "sheet-on-sheet" architecture (2D ReS2/RGO) or a three-dimensional hierarchical structure (3D ReS2/RGO) are constructed through rational structure-engineering strategies. In the resultant 3D ReS2/RGO heteronanosheets, the ultrathin ReS2 nanosheets are bridged on the RGO surface through Re-O bonds in a vertically oriented manner, which endows the heteronanosheets with open frameworks and a hierarchical porous structure. In sharp contrast to the 2D ReS2/RGO, the 3D ReS2/RGO heteronanosheets are featured with abundant active sites and channels for efficient electrolyte ions transport. This, coupled with the strong affinity toward oxygen-containing intermediates intrinsically associated with the binary ReS2/RGO structure, imparts excellent oxygen reduction performance to the 3D ReS2/RGO heteronanosheets for potential applications in fuel cells and metal-air batteries.
RESUMO
BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in combination with second controller medications in the management of asthma in adults and children. There lacks a systematic comparison between addition of leukotriene receptor antagonists (LTRAs) and theophylline to ICS. The purpose of this meta-analysis was to evaluate the difference of the efficacy and safety profile of adding either LTRAs or theophylline to ICS in adults and children with symptomatic asthma. METHODS: Randomised controlled trials (RCTs) published prior to November 2014 were acquired through systematically searching and selected based on the established inclusion criteria for publications. The data extracted from the included studies were further analyzed by a meta-analysis. RESULTS: We included eight RCTs, of which six recruited adults and two recruited children aged 5 to 14 years. The primary outcomes were changes in lung function from baseline, including forced expiratory volume in the first second (FEV1) and peak expiratory flow (PEF). Overall, addition of LTRAs led to significantly better morning PEF {mean difference (MD) 16.94 [95% confidence interval (CI): 11.49-22.39] L/min, P<0.01} and FEV1 [MD 0.09 (95% CI: 0.03-0.15) L, P=0.005] as compared to addition of theophylline. There were no differences between the two treatments in terms of evening PEF, adverse events, rescue medication use and asthma exacerbation. CONCLUSIONS: The combination of LTRA and ICS leads to modestly greater improvement in lung function than the combination of theophylline and ICS in the treatment of symptomatic asthma. Long-term trials are required to assess the efficacy and safety of these two therapies.
RESUMO
BACKGROUND: Standard triple therapy for Helicobacter pylori infection fails in up to one quarter of patients. Levofloxacin-based triple therapy may be more efficacious. OBJECTIVE: The aim of this paper was to compare levofloxacin and proton pump inhibitor-based triple therapy with standard triple therapy for H. pylori infection. METHODS: PubMed, Embase, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, Google Scholar, and Ovid were systematically searched to identify randomized controlled trials comparing levofloxacin and proton pump inhibitor-based therapy with standard triple therapy in treatment-naive patients with H. pylori infection until August 2013. RESULTS: Ten randomized controlled trials involving 2676 patients (1357 in the levofloxacin group and 1319 in the control group) met the inclusion criteria. The pooled odds ratio by intention-to-treat analysis and by per protocol analysis in the levofloxacin regimen versus standard regimen was 1.28 [95% confidence interval (CI): 0.88-1.85] and 1.23 (95% CI: 0.82-1.84) by the random effects model, respectively. There was no statistical significance of the incidence of total side effects between the groups, but levofloxacin-based therapy was associated with a significant reduction in the incidence of taste disturbance compared with standard third therapy. CONCLUSION: Levofloxacin-based therapy was as safe and effective as triple therapy for H. pylori infection and could be considered as an additional treatment option. However, more rigorous research is required to accurately assess the role of levofloxacin in eradicating H. pylori infection.
